<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00615173</url>
  </required_header>
  <id_info>
    <org_study_id>SYSU-PRGLN-001</org_study_id>
    <nct_id>NCT00615173</nct_id>
  </id_info>
  <brief_title>Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Induction and Maintenance Phase Treatment in Lupus Nephritis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of tacrolimus vs intravenous
      cyclophosphamide pulses treatment for the induction therapy of LN(III,IV,V).

      To compare the efficacy and safety of tacrolimus vs Azathioprine for the maintenance therapy
      of LN(III,IV,V).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission rate</measure>
    <time_frame>2006-2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function, proteinuria, relapse.</measure>
    <time_frame>2006-2008</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Kidney Diseases</condition>
  <condition>Lupus Nephritis</condition>
  <condition>Tacrolimus</condition>
  <condition>Induction Phase</condition>
  <condition>Maintenance Phase</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tacrolimus(fk506) treatment in induction and maintenance phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous cyclophosphamide pulses treatment in induction phase; and Aza in the maintenance phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus (FK506)</intervention_name>
    <description>Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide or azathioprine</intervention_name>
    <description>Induction phase: CTX 0.75g/m2 monthly Maintenance phase: AZA 2mg/kg/d.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects of either sex, 14-65 years of age;

          2. Diagnosis of SLE according to the ACR criteria(1997);

          3. Kidney biopsy within the 6 months prior to first randomization with a histologic
             diagnosis (ISN/RPS 2003 classification of LN) class III, IV, V;

          4. Class IV LN: proteinuria &gt;1g/24hr or Scr&gt;115umol/L;

          5. Class III or V LN: proteinuria &gt;2g/24hr or Scr&gt;115umol/L;

          6. Provision of written informed consent by subject or guardian.

        Exclusion Criteria:

          1. Inability or unwillingness to provide written informed consent ;

          2. Known hypersensitivity or contraindication to tacrolimus, cyclophosphamide ,
             azathioprine, corticosteroids;

          3. Usage of immunosuppression therapy (MMF, CTX, CysA, MTX ect) for more than 1 week
             within 1 month prior to first randomization;

          4. Pregnancy, nursing or use of a non-reliable method of contraception;

          5. Continuous dialysis starting more than 2 weeks before randomization into the induction
             phase and/or continuous dialysis with an anticipated duration of more than 8 weeks;

          6. Previous kidney transplant or planted transplant;

          7. Scr &gt; 4mg/dl (353umol/L);

          8. Active hepatitis, with liver dysfunction;

          9. Diagnosed DM;

         10. Participation in another clinic trial and/or receipt of investigational drugs within 4
             weeks prior to screening .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xue Qing Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, 1st Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ping Fu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, West China Hospital of Sichuan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yun Hua Liao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, 1st Affiliated Hospital of Guangxi Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin li Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of nephrology, People's Hospital of Yunnan Province</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jian Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, Fuzhou Military General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tan Qi Lou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, 3rd Affiliated Hospital of Sun Yet-Sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yao zhong Kong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, 1st People's Hospital of Foshan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun zhou Fu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology,1st People's Hospital of Guangzhou</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wei Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, People's Hospital Guangdong Provincial</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zheng rong Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The 1st Affiliated Hospital, Sun Yet-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2008</study_first_submitted>
  <study_first_submitted_qc>February 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2008</study_first_posted>
  <last_update_submitted>October 27, 2008</last_update_submitted>
  <last_update_submitted_qc>October 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Xueqing Yu</name_title>
    <organization>Sun Yat-sen University</organization>
  </responsible_party>
  <keyword>Tacrolimus</keyword>
  <keyword>lupus nephritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

